Cingulate Inc (NASDAQ:CING) — Market Cap & Net Worth
Market Cap & Net Worth: Cingulate Inc (CING)
Cingulate Inc (NASDAQ:CING) has a market capitalization of $62.45 Million ($62.45 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21019 globally and #4500 in its home market, demonstrating a -4.45% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cingulate Inc's stock price $5.37 by its total outstanding shares 11628613 (11.63 Million). Analyse Cingulate Inc operating cash flow efficiency to see how efficiently the company converts income to cash.
Cingulate Inc Market Cap History: 2021 to 2026
Cingulate Inc's market capitalization history from 2021 to 2026. Data shows change from $7.70 Billion to $62.45 Million (-69.99% CAGR).
Index Memberships
Cingulate Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #602 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2028 of 3165 |
Weight: Cingulate Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cingulate Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cingulate Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CING by Market Capitalization
Companies near Cingulate Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Cingulate Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Cingulate Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Cingulate Inc's market cap moved from $7.70 Billion to $ 62.45 Million, with a yearly change of -69.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $62.45 Million | +23.73% |
| 2025 | $50.47 Million | -11.97% |
| 2024 | $57.33 Million | -94.63% |
| 2023 | $1.07 Billion | -61.75% |
| 2022 | $2.79 Billion | -63.77% |
| 2021 | $7.70 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Cingulate Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $62.45 Million USD |
| MoneyControl | $62.45 Million USD |
| MarketWatch | $62.45 Million USD |
| marketcap.company | $62.45 Million USD |
| Reuters | $62.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cingulate Inc
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It … Read more